Alnylam Pharmaceuticals, Inc.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US02043Q1076
USD
357.98
53.98 (17.76%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Net Sales
1,249.03
773.69
594.19
593.17
500.92
659.83
494.33
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,249.03
773.69
594.19
593.17
500.92
659.83
494.33
Raw Material Cost
200.15
142.95
71.04
102.82
85.91
68.67
65.98
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
44.40
40.25
38.65
38.97
34.38
33.26
35.25
Selling and Distribution Expenses
322.08
323.31
239.95
295.34
220.99
248.40
210.80
Other Expenses
31.44
28.34
22.65
26.12
23.65
26.09
22.57
Total Expenditure (Excl Depreciation)
881.04
789.89
576.11
698.33
577.82
611.21
537.77
Operating Profit (PBDIT) excl Other Income
368
-16.200000000000003
18.1
-105.19999999999999
-76.9
48.6
-43.4
Other Income
19.19
36.35
37.86
20.44
38.89
29.12
23.69
Operating Profit (PBDIT)
400.98
34.09
70.35
-70.55
-24.03
92.74
-6.23
Interest
44.40
40.25
38.65
38.97
34.38
33.26
35.25
Exceptional Items
-103.81
-15.26
-58.89
-70.27
-36.27
-55.64
-8.59
Gross Profit (PBDT)
1,048.87
630.74
523.15
490.35
415.01
591.15
428.36
Depreciation
13.80
13.94
14.40
14.17
13.98
15.00
13.52
Profit Before Tax
238.97
-35.36
-41.60
-193.96
-108.66
-11.17
-63.59
Tax
-12.12
30.92
15.88
-110.19
2.91
5.72
2.35
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
251.08
-66.28
-57.48
-83.76
-111.57
-16.89
-65.94
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
251.08
-66.28
-57.48
-83.76
-111.57
-16.89
-65.94
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
251.08
-66.28
-57.48
-83.76
-111.57
-16.89
-65.94
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Reserves
233.89
250.59
115.44
67.09
32.35
-3.07
-219.27
Earnings per share (EPS)
1.84
-0.51
-0.44
-0.65
-0.87
-0.13
-0.52
Diluted Earnings per share
1.84
-0.51
-0.44
-0.65
-0.87
-0.13
-0.52
Operating Profit Margin (Excl OI)
29.46%
-2.09%
3.04%
-17.73%
-15.35%
7.37%
-8.79%
Gross Profit Margin
20.24%
-2.77%
-4.58%
-30.31%
-18.9%
0.58%
-10.13%
PAT Margin
20.1%
-8.57%
-9.67%
-14.12%
-22.27%
-2.56%
-13.34%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Sep 2025 is 61.43% vs 30.21% in Jun 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Sep 2025 is 478.73% vs -15.30% in Jun 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Sep 2025 is 16,700.00% vs -107.08% in Jun 2025

stock-summary

Interest

QoQ Growth in quarter ended Sep 2025 is 10.45% vs 4.15% in Jun 2025

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

Compare Quarterly Results Of Alnylam Pharmaceuticals, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
1,249.03
944.96
304.07
32.18%
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,249.03
944.96
304.07
32.18%
Raw Material Cost
200.15
219.96
-19.81
-9.01%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
44.40
16.53
27.87
168.60%
Selling and Distribution Expenses
322.08
433.22
-111.14
-25.65%
Other Expenses
31.44
13.35
18.09
135.51%
Total Expenditure (Excl Depreciation)
881.04
803.21
77.83
9.69%
Operating Profit (PBDIT) excl Other Income
367.98
141.75
226.23
159.60%
Other Income
19.19
-0.32
19.51
6,096.88%
Operating Profit (PBDIT)
400.98
237.73
163.25
68.67%
Interest
44.40
16.53
27.87
168.60%
Exceptional Items
-103.81
10.35
-114.16
-1,103.00%
Gross Profit (PBDT)
1,048.87
725.00
323.87
44.67%
Depreciation
13.80
96.30
-82.50
-85.67%
Profit Before Tax
238.97
135.25
103.72
76.69%
Tax
-12.12
8.18
-20.30
-248.17%
Provisions and contingencies
0
0.00
0.00
Profit After Tax
251.08
127.07
124.01
97.59%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
251.08
127.07
124.01
97.59%
Share in Profit of Associates
0
0.00
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
251.08
127.07
124.01
97.59%
Equity Capital
0
0
0.00
Face Value
0.01
0.00
0.00
Reserves
233.89
5,310.96
-5,077.07
-95.60%
Earnings per share (EPS)
1.84
0.54
1.30
240.74%
Diluted Earnings per share
1.84
0.54
1.30
240.74%
Operating Profit Margin (Excl OI)
29.46%
15.00%
0.00
14.46%
Gross Profit Margin
20.24%
24.50%
0.00
-4.26%
PAT Margin
20.10%
13.45%
0.00
6.65%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 124.90 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 61.43% vs 30.21% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 149.35% vs -33.26% in Sep 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 25.11 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 478.73% vs -15.30% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 325.00% vs -175.51% in Sep 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 38.18 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 16,700.00% vs -107.08% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 707.00% vs -127.68% in Sep 2024

Quarterly - Interest
Interest 4.44 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 10.45% vs 4.15% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 29.07% vs 11.33% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 29.46%
in Sep 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 has improved from Sep 2024